All In Biotech

Free tool

FAERS Monitor: Relpax

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021016 or its brand name (Relpax, Eletriptan Hydrobromide). Reports on generic versions are filed under their own applications.

Reports

7,038

Serious

3,693

52% of reports

Hospitalization

1,236

Death reported

97

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective913
  • migraine863
  • headache733
  • nausea502
  • pain425
  • fatigue335
  • vomiting329
  • malaise292
  • dizziness270
  • off label use231
  • anxiety223
  • feeling abnormal214
  • dyspnoea207
  • insomnia202
  • condition aggravated197

Reports by year received

View as table
YearReports
2004208
2005183
2006112
2007131
2008134
200975
2010322
2011282
2012451
2013408
2014478
2015618
2016689
2017406
2018392
2019672
2020415
2021244
2022256
2023170
2024177
2025129
202686

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,121 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
migraineSignal86327.325.621,701
headacheSignal7333.53.31,343
feeling abnormalSignal2142.72.3224
anxietySignal2232.32.1172
insomniaSignal2022.32.0144
vomitingSignal3292.11.9191
drug ineffectiveSignal9132.11.9538
painSignal4252.11.9240
malaise2922.01.8146
condition aggravated1971.91.790
nausea5021.91.7220
dizziness2701.61.465
fatigue3351.31.222
dyspnoea2071.11.02
off label use2310.80.713

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.